arrow
F

Franck Carbonnel

assistance publique hopitaux paris (aphp)
H指数:76
被引数:3.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Five-year effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor

239例对肿瘤坏死因子拮抗剂无应答的克罗恩病患者中,ustekinumab或vedolizumab的五年疗效。

2025-12-050
PRE
Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study

炎症性肠病患者停用 vedolizumab 和 ustekinumab 后的复发率——一项多中心回顾性对照研究。VEDUST-EXIT 研究

2025-10-270
PRE
Blood proteomic signatures associated with disease activity in inflammatory bowel diseases

与炎症性肠病疾病活动度相关的血液蛋白质组学特征

2025-09-010
PRE
Collagenous colitis in patients treated for cancer: role of immune checkpoint inhibitors. Clinical, histological and immunological features in 15 cases

胶原性结肠炎在癌症治疗患者中的发生:免疫检查点抑制剂的潜在作用。15例患者的临床、组织学和免疫学特征

2025-08-060
OAAI
A randomized controlled trial of antibiotics targeting adherent and invasive Escherichia coli versus placebo in Crohn's disease: the TEOREM trial

针对黏附侵袭性大肠杆菌的抗生素与安慰剂在克罗恩病中的随机对照试验:TEOREM试验。J. Crohns Colitis 19, jjaf093

2025-07-012
PRE
Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study
2025-01-220
PRE
Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis

饮食的炎症潜力与克罗恩病和溃疡性结肠炎的风险

2025-01-162
PRE
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations

跨肿瘤适应症的免疫治疗联合化疗的毒性: 当前知识和实用建议

2024-06-019
OAAI
Dietary index based on the Food Standards Agency nutrient profiling system and risk of Crohn's disease and ulcerative colitis

基于食品标准局营养分析系统的膳食指数以及克罗恩病和溃疡性结肠炎的风险

2023-12-154
OAAI